198 results on '"Amifampridine"'
Search Results
2. Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
3. Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
4. Treatment Use of 3,4-Diaminopyridine
5. Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3 (SMA3)
6. Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome (EAP-001)
7. Pyridostigmine and Amifampridine for Myasthenia Gravis (IMPACT-MG)
8. Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia
9. Firdapse for Post-BOTOX Vocal Weakness
10. 3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS) (LEMS)
11. Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome (3 4-DAP)
12. Investigation of N -Acetyltransferase 2-Mediated Drug Interactions of Amifampridine: In Vitro and In Vivo Evidence of Drug Interactions with Acetaminophen.
13. Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients
14. Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
15. Clinical and Pathologic Features of Congenital Myasthenic Syndromes Caused by 35 Genes—A Comprehensive Review.
16. 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
17. Amifampridine safety and efficacy in spinal muscular atrophy ambulatory patients: a randomized, placebo-controlled, crossover phase 2 trial.
18. 3,4‐diaminopyridine base effectively treats the weakness of Lambert‐Eaton myasthenia
19. A catalyst for change? Orphan drugs and the case of C atalyst v. Becerra.
20. The European Lambert–Eaton Myasthenic Syndrome Registry: Long-Term Outcomes Following Symptomatic Treatment.
21. Treatment of Lambert-Eaton Syndrome With 3,4 DAP
22. Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
23. Investigation of N-Acetyltransferase 2-Mediated Drug Interactions of Amifampridine: In Vitro and In Vivo Evidence of Drug Interactions with Acetaminophen
24. Population Pharmacokinetics/Pharmacodynamics of 3,4‐Diaminopyridine Free Base in Patients With Lambert‐Eaton Myasthenia
25. A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
26. Amifampridine overdose leading to refractory status epilepticus.
27. Safety, efficacy and steroid-sparing effect of amifampridine in Lambert-Eaton myasthenic syndrome patients - real world data.
28. Foodborne botulism outbreak with potential new management options.
29. Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (DAPPER)
30. Management/Treatment of Lambert-Eaton Myasthenic Syndrome.
31. Congenital Myasthenic Syndromes
32. Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome (34-DAP)
33. Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism
34. Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
35. Probing the Strength and Mechanism of Binding Between Amifampridine and Calf Thymus DNA.
36. CE. New Drugs 2020.
37. Amifampridine for the Management of Lambert-Eaton Myasthenic Syndrome: A New Take on an Old Drug.
38. Amifampridine tablets for the treatment of Lambert-Eaton myasthenic syndrome.
39. New Charge Transfer Complexes of K+-Channel-Blocker Drug (Amifampridine; AMFP) for Sensitive Detection; Solution Investigations and DFT Studies
40. Reduced Fatigue Symptoms in the Post-COVID Syndrome With Amifampridine: A Collective Casuistry With Double-Blind Discontinuation Trials.
41. Complexation of drug amifampridine with Cu(II), Zn(II) and Cd(II) ions, and its dimerization with the magic of Mn(II) salts. Potential anti-COVID-19 and anticancer activities.
42. Amifampridine for the treatment of Lambert-Eaton myasthenic syndrome.
43. Antidotal treatment of botulism in rats by continuous infusion with 3,4-diaminopyridine
44. Catalyst and KYE challenging Health Canada issuance of NOC for Ruzurgi
45. Amifampridine safety and efficacy in spinal muscular atrophy ambulatory patients: a randomized, placebo-controlled, crossover phase 2 trial
46. Findings from University Hospitals Cleveland Medical Center Provides New Data on Lambert-Eaton Myasthenic Syndrome (Recent Advances and Therapeutic Options in Lambert-Eaton Myasthenic Syndrome)
47. Acetylator Status Impacts Amifampridine Phosphate (Firdapse™) Pharmacokinetics and Exposure to a Greater Extent Than Renal Function.
48. Neuromuscular junction disorders beyond myasthenia gravis
49. AMFP) for Sensitive Detection
50. Management/Treatment of Lambert-Eaton Myasthenic Syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.